- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02617732
Effects of Tianqi Capsule on Glucose Variability in Patients With Type 2 Diabetes.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Diabetes has become a threat to human health and an independent risk factor to macrovascular and microvascular diseases. Large prospective clinical studies have shown a strong relationship between time-averaged mean levels of glycemia as measured by HbA1c and diabetes complications. However, in recent years several pieces of evidence indicated that glucose variability may also contribute to the development of diabetes complications. Thus, glucose variability may become a new target in treatment of diabetes. Traditional Chinese medicine,a kind of multitargeted compound, may contribute to maintaining blood glucose homeostasis in diabetes.
Tianqi capsule(Chinese herbs extract) is a Chinese patent medicine approved to treat T2DM in China. Previous clinical studies have shown that Tianqi capsule could lower blood glucose measured by HbA1c. What's more, Tianqi capsule has also been proved to improve the glycometabolism and lipid metabolism in T2DM and IGT.
This research adopts a randomized, open, parallel double blind, placebo controlled clinical method. The patients, meeting eligibility criteria, are divided into experimental group and placebo group and treated for 12 weeks . A main outcome,glucose variability is detected by continuous blood glucose monitoring system which could obtain continuous and comprehensive blood glucose by "glucose sensor". The influence of Tianqi capsule on glucose variability in type 2 diabetes will be evaluated.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Qian Zhang, Doctor
- Phone Number: (86+)13810387388
- Email: qianqian0409@163.com
Study Contact Backup
- Name: Zhen Tang, Master
- Phone Number: (86+)18810941269
- Email: 1225530172@qq.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Peking Union Medical College Hospital traditional Chinese medicine department
-
Contact:
- Qian Zhang, Doctor
- Phone Number: (86+)13810387388
- Email: qianqian0409@163.com
-
Contact:
- Zhen Tang, Master
- Phone Number: (86+)18810941269
- Email: 1225530172@qq.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- 18.5kg/m2≤BMI≤35.0 kg/m2;
- meet type 2 diabetes mellitus diagnostic criteria published by 1999 WHO;
- with blood variability, defined as standard deviation of blood glucose more than 3.5mmol/L within 2 days by self-monitoring of blood glucose(SMBG)(more than 5 times per day)
- diabetic duration more than 1 year; in stable condition for more than 4 weeks with unchanged lifestyle and other drugs intervention; (permit taking metformin or sulphonylureas which dosage is unchanged during study period )
- HbA1c≤10%;
- signed the informed consent form.
Exclusion Criteria:
- have acute diabetes complications (e.g. diabetic ketoacidosis,diabetic hyperosmolar coma,diabetic lactic acidosis,Hypoglycemic coma)
- have severe chronic diabetes complications(e.g. diabetic retinopathy stage 4~6,severe diabetic nephropathy needs dialysis and so on)
- have gastrointestinal disease which have serious influence on digestive function and disorder of absorption
- have other endocrine disease (hyperthyroidism,acromegaly,Cushing's syndrome and so on.)
- have severe heart disease(such as acute myocardium infarction, unstable angina,heart failure NYHA functional classification III or IV)
- have moderate or severe liver function abnormality(ALT,TBil or AST> double upper limit )
- have moderate and severe renal function abnormality(eGFR < 50ml/min)
- blood leukocyte <4.0×10^9/L; blood thrombocyte<90×10^9/L
- taking drugs affecting glucose metabolism,such as glucocorticoid
- have other serious illness which considered to exacerbate and be life-threaten during fellow up period;
- have evidence of mental disorders;
- alcoholics and drug abuse
- females who were pregnant, lactating, planning for pregnancy, or sexually active but with no contraceptive measures;
- have participated in clinical trials within 3 months before;
- other conditions researchers thought to unable to evaluate the curative effect and finish the study.
- allergic to the ingredients of herbs contained in Tianqi capsule
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tianqi capsule
a Chinese patent medicine extracted form more than10 kinds of herbs, which was approved to treat type 2 diabetes by CDFA in 2002.
|
The patients with type 2 diabetes are divided into two groups, one is experimental group, and the other is placebo group. The experimental group patients are treated with Tianqi capsule by oral, 5 pills three times a day
Other Names:
|
Placebo Comparator: placebo
a capsule looks the same as Tianqi capsule, containing starch and other edible compositions.
|
The patients with type 2 diabetes are divided into two groups, one is experimental group, the other is placebo group. The placebo group patients are treated with placebo by oral, 5 pills three times a day |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in mean amplitude of glycemic excursions (MAGE) and mean of daily differences (MODD) at 12 weeks.
Time Frame: 12 weeks
|
Glucose variability is evaluated by continuous glucose monitoring system, the main parameters include mean amplitude of glycemic excursions (MAGE)(mmol/L) and mean of daily differences (MODD)(mmol/L).
The amplitude of glycemic excursions(AGE)is obtained by continuous glucose, MAGE is calculated using the criterion that both segments of the amplitude of glycemic excursions (AGE) exceed 1 SD, the calculations were carried out as described below, using the formula: MAGE (mg/dL)=∑AGE/n (n=number of glycemic excursions>1 SD).
The MODD was calculated as the mean of the absolute difference of glucose values from corresponding times of day from two consecutive days.
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in serum lipid and lipoprotein at 12 weeks.
Time Frame: 12 weeks
|
Serum lipid and lipoprotein including: triglyceride (TC) (mmol/L); total cholesterol (TG) (mmol/L); low density lipoprotein cholesterol (LDL-C) (mmol/L); high density lipoprotein cholesterol (HDL-C) (mmol/L)
|
12 weeks
|
Change from baseline in hemoglobin A1c(HbA1c) at 12 weeks
Time Frame: 12 weeks
|
12 weeks
|
|
Liver Function Examination
Time Frame: 4 weeks
|
Liver function examination including alanine aminotransferase (ALT) (U/L) and aspartate transaminase (AST) (U/L).
|
4 weeks
|
Renal Function Examination
Time Frame: 4 weeks
|
Renal function examination including blood urea nitrogen(BUN)(mmol/L)and urine creatinine(UCr) (mmol/d).
|
4 weeks
|
Collaborators and Investigators
Investigators
- Study Director: Xiaochun Liang, Doctor, Peking Union Medical College Hospital traditional Chinese medicine department
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PUMCH-TCM-TQGV-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Diabetes Foundation, IndiaNational Diabetes Obesity and Cholesterol FoundationRecruitingType 2 Diabetes Mellitus With ComplicationIndia
Clinical Trials on Tianqi capsule
-
Xinhua Hospital, Shanghai Jiao Tong University...Xin Hua Hospital of Zhejiang Province; Huai'an First People's Hospital; Nanjing... and other collaboratorsUnknownLevodopa-Induced DyskinesiaChina
-
Quan JiangUnknown
-
Guizhou Bailing Group Pharmaceutical Co LtdWangjing Hospital, China Academy of Chinese Medical Sciences; The First Affiliated... and other collaboratorsUnknownKnee OsteoarthritisChina
-
Jonsson Comprehensive Cancer CenterWithdrawnAcute Graft Versus Host Disease | Gastrointestinal Tract Acute Graft Versus Host Disease | Severe Gastrointestinal Tract Acute Graft Versus Host Disease | Steroid Resistant Gastrointestinal Tract Acute Graft Versus Host DiseaseUnited States
-
Yung Shin Pharm. Ind. Co., Ltd.Changhua Christian HospitalCompletedHot Flashes | PMSTaiwan
-
Chipscreen Biosciences, Ltd.Not yet recruiting
-
Burapha UniversityCompletedAsparagus Capsule ConsumptionThailand
-
Vibrant Ltd.CompletedConstipationUnited States
-
Vibrant Ltd.UnknownConstipationUnited States
-
Hanmi Pharmaceutical Company LimitedUnknownChronic Obstructive Pulmonary Disease